Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Norfolk Southern Corporation (NSC) vs Twist Bioscience Corp (TWST) Price & Performance

Norfolk Southern CorporationTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Norfolk Southern Corporation vs Twist Bioscience Corp — how do they compare? Norfolk Southern Corporation trades at $317.79 (market cap $71.20B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Norfolk Southern Corporation is far larger — about 7.1× Twist Bioscience Corp's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Twist Bioscience Corp for 27 Days on average.

NSCTWST
Market Cap
$71.20B$10.08B
Volume
555,2484,229,037
Sector
IndustrialsHealth
52-Week High
$352.98$205.00
52-Week Low
$278.19$25.45
Typical Hold Time
33 Days27 Days
Enterprise Value
$86.75B$10.01B
Dividend Yield
1.7%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Norfolk Southern Corporation

Norfolk Southern (NSC) trades at $316.99, up 1.21% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, a 21.02% net income margin, and a 16.97% ROE. Recent news highlights progress on the Union Pacific merger, expected to close by late 2027, and a dividend of $1.35 payable in August 2026. Cash flow remains positive from operations despite net outflows.

NSC presents a favorable investment case with analyst consensus at Buy and a $361.86 price target, implying 14% upside. Key risks include merger regulatory hurdles and fuel cost pressures. The combination with Union Pacific offers long-term growth potential, but investors should monitor STB approval timelines and operating ratio trends.

Twist Bioscience Corp

TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.

Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NSC

No sentiment data available yet.

TWST
100% Buy0% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Norfolk Southern Corporation

Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.

Read more on NSC →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →